Please assess the completion status of the following clinical trial:

Trial Title: Aneuploidies in Embryos and Spermatozoa From Patients With Y-chromosome Microdeletions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Couples with male infertility whose man has non-obstructive azoospermia or severe oligozoospermia with ≤5x1000000 spermatozoa/ml.~2. Assisted Reproductive Technology: ICSI with motile spermatozoa and PGS by CGH arrays.~3. Women \<38 years if microinjection is carried out in their own eggs, or 38≤ age \<50 years if they receive donated eggs.~4. Women with body mass index (BMI)\<30.~5. Men\<50 years~Exclusion Criteria:~1. Couples with abnormal karyotypes.~2. Women with any uterine pathology or abnormality, hydrosalpinx, thrombophilia or systemic diseases at the time of embryo transfer that could prejudge the outcome of the cycle~3. Couples with repeated miscarriages (≥2) or implantation failures (≥2).~4. Couples whose men has obstructive azoospermia, genital tract infections (mumps, inflammation, varicocele), cryptorchidism, or if he receives any treatment that can reduce the sperm count.~5. Seminal samples processed by Magnetic Activated Cell Sorting (MACS) technique.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Infertile with Y-chromosome deletions (Type: None): No intervention will be performed.~Couples whose infertile men has a Y-chromosome microdeletion (detected in blood cells by Polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 1)
- Infertile without Y-chromosome deletions (Type: None): No intervention will be performed.~Couples whose infertile men has not any Y-chromosome microdeletion (detected in blood cells by polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).